Oncology Net Income From Continuing Ops vs Cost Of Revenue Analysis

TOIIW Stock

USD 0.02 0 26.85%

Oncology Institute financial indicator trend analysis is much more than just breaking down The Oncology Institute prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether The Oncology Institute is a good investment. Please check the relationship between Oncology Institute Net Income From Continuing Ops and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in The Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of The Oncology Institute Net Income From Continuing Ops account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Oncology Institute's Net Income From Continuing Ops and Cost Of Revenue is -0.81. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of The Oncology Institute, assuming nothing else is changed. The correlation between historical values of Oncology Institute's Net Income From Continuing Ops and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of The Oncology Institute are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income From Continuing Ops i.e., Oncology Institute's Net Income From Continuing Ops and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.81

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income From Continuing Ops

Cost Of Revenue

Cost of Revenue is found on The Oncology Institute income statement and represents the costs associated with goods and services Oncology Institute provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Oncology Institute's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into The Oncology Institute current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in The Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.Tax Provision is likely to climb to about (84.5 K) in 2024. Selling General Administrative is likely to drop to about 67.6 M in 2024

	2021	2022	2023	2024 (projected)
Interest Expense	320K	4.1M	6.8M	7.1M
Depreciation And Amortization	3.3M	4.4M	5.9M	3.8M

Interest Expense Depreciation And Amortization

Oncology Institute fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Non Current Liabilities Other	Net Working Capital
Common Stock Shares Outstanding		0.84	0.85	0.88	0.68	0.74	0.4	-0.78	0.69	0.53	0.7	0.8	0.79	0.8	0.31	0.83	0.76	0.78	0.89	0.86	0.78	0.72	0.82	-0.67	0.25	0.79
Total Assets	0.84		0.98	0.86	0.9	0.82	0.4	-0.78	0.65	0.64	0.86	0.91	0.94	0.91	0.45	0.98	0.86	0.91	0.96	0.97	0.98	0.79	0.97	-0.91	0.35	0.96
Other Current Liab	0.85	0.98		0.92	0.84	0.8	0.33	-0.85	0.78	0.73	0.75	0.94	0.97	0.89	0.4	0.97	0.88	0.96	0.98	0.98	0.94	0.79	0.99	-0.9	0.43	0.98
Total Current Liabilities	0.88	0.86	0.92		0.63	0.78	0.38	-0.91	0.87	0.63	0.63	0.89	0.86	0.84	0.23	0.88	0.85	0.87	0.97	0.92	0.77	0.78	0.89	-0.68	0.3	0.85
Total Stockholder Equity	0.68	0.9	0.84	0.63		0.59	0.18	-0.5	0.43	0.64	0.85	0.66	0.84	0.68	0.75	0.79	0.57	0.81	0.77	0.78	0.89	0.55	0.84	-0.85	0.5	0.86
Property Plant And Equipment Net	0.74	0.82	0.8	0.78	0.59		0.79	-0.9	0.53	0.29	0.76	0.87	0.68	0.93	-0.07	0.88	0.91	0.64	0.82	0.88	0.83	1.0	0.76	-0.8	-0.16	0.74
Net Debt	0.4	0.4	0.33	0.38	0.18	0.79		-0.55	0.0	-0.36	0.63	0.48	0.12	0.69	-0.41	0.5	0.61	0.06	0.38	0.49	0.47	0.79	0.25	-0.33	-0.71	0.21
Retained Earnings	-0.78	-0.78	-0.85	-0.91	-0.5	-0.9	-0.55		-0.83	-0.52	-0.54	-0.9	-0.77	-0.85	0.06	-0.85	-0.9	-0.77	-0.88	-0.87	-0.72	-0.92	-0.82	0.74	-0.08	-0.79
Accounts Payable	0.69	0.65	0.78	0.87	0.43	0.53	0.0	-0.83		0.83	0.22	0.74	0.82	0.55	0.19	0.67	0.66	0.86	0.81	0.71	0.52	0.55	0.8	-0.58	0.55	0.76
Cash	0.53	0.64	0.73	0.63	0.64	0.29	-0.36	-0.52	0.83		0.21	0.58	0.86	0.35	0.59	0.57	0.43	0.89	0.67	0.59	0.54	0.28	0.79	-0.67	0.89	0.8
Non Current Assets Total	0.7	0.86	0.75	0.63	0.85	0.76	0.63	-0.54	0.22	0.21		0.68	0.63	0.84	0.42	0.81	0.68	0.58	0.74	0.8	0.9	0.71	0.7	-0.71	-0.01	0.7
Non Currrent Assets Other	0.8	0.91	0.94	0.89	0.66	0.87	0.48	-0.9	0.74	0.58	0.68		0.89	0.95	0.1	0.98	0.98	0.86	0.94	0.98	0.9	0.87	0.94	-0.86	0.21	0.92
Cash And Short Term Investments	0.79	0.94	0.97	0.86	0.84	0.68	0.12	-0.77	0.82	0.86	0.63	0.89		0.77	0.49	0.91	0.79	0.99	0.93	0.91	0.88	0.66	0.99	-0.9	0.61	0.99
Net Receivables	0.8	0.91	0.89	0.84	0.68	0.93	0.69	-0.85	0.55	0.35	0.84	0.95	0.77		0.08	0.97	0.97	0.73	0.91	0.96	0.93	0.91	0.85	-0.81	-0.01	0.83
Good Will	0.31	0.45	0.4	0.23	0.75	-0.07	-0.41	0.06	0.19	0.59	0.42	0.1	0.49	0.08		0.25	-0.05	0.51	0.33	0.25	0.4	-0.12	0.42	-0.35	0.76	0.45
Non Current Liabilities Total	0.83	0.98	0.97	0.88	0.79	0.88	0.5	-0.85	0.67	0.57	0.81	0.98	0.91	0.97	0.25		0.95	0.87	0.96	1.0	0.97	0.86	0.95	-0.89	0.23	0.94
Inventory	0.76	0.86	0.88	0.85	0.57	0.91	0.61	-0.9	0.66	0.43	0.68	0.98	0.79	0.97	-0.05	0.95		0.76	0.9	0.95	0.87	0.9	0.86	-0.81	0.04	0.84
Other Current Assets	0.78	0.91	0.96	0.87	0.81	0.64	0.06	-0.77	0.86	0.89	0.58	0.86	0.99	0.73	0.51	0.87	0.76		0.93	0.89	0.83	0.63	0.98	-0.86	0.65	0.97
Other Stockholder Equity	0.89	0.96	0.98	0.97	0.77	0.82	0.38	-0.88	0.81	0.67	0.74	0.94	0.93	0.91	0.33	0.96	0.9	0.93		0.98	0.9	0.8	0.96	-0.82	0.35	0.94
Total Liab	0.86	0.97	0.98	0.92	0.78	0.88	0.49	-0.87	0.71	0.59	0.8	0.98	0.91	0.96	0.25	1.0	0.95	0.89	0.98		0.95	0.86	0.96	-0.87	0.25	0.94
Net Invested Capital	0.78	0.98	0.94	0.77	0.89	0.83	0.47	-0.72	0.52	0.54	0.9	0.9	0.88	0.93	0.4	0.97	0.87	0.83	0.9	0.95		0.79	0.92	-0.92	0.26	0.93
Property Plant And Equipment Gross	0.72	0.79	0.79	0.78	0.55	1.0	0.79	-0.92	0.55	0.28	0.71	0.87	0.66	0.91	-0.12	0.86	0.9	0.63	0.8	0.86	0.79		0.74	-0.78	-0.17	0.72
Total Current Assets	0.82	0.97	0.99	0.89	0.84	0.76	0.25	-0.82	0.8	0.79	0.7	0.94	0.99	0.85	0.42	0.95	0.86	0.98	0.96	0.96	0.92	0.74		-0.91	0.5	1.0
Capital Stock	-0.67	-0.91	-0.9	-0.68	-0.85	-0.8	-0.33	0.74	-0.58	-0.67	-0.71	-0.86	-0.9	-0.81	-0.35	-0.89	-0.81	-0.86	-0.82	-0.87	-0.92	-0.78	-0.91		-0.36	-0.94
Non Current Liabilities Other	0.25	0.35	0.43	0.3	0.5	-0.16	-0.71	-0.08	0.55	0.89	-0.01	0.21	0.61	-0.01	0.76	0.23	0.04	0.65	0.35	0.25	0.26	-0.17	0.5	-0.36		0.52
Net Working Capital	0.79	0.96	0.98	0.85	0.86	0.74	0.21	-0.79	0.76	0.8	0.7	0.92	0.99	0.83	0.45	0.94	0.84	0.97	0.94	0.94	0.93	0.72	1.0	-0.94	0.52

Click cells to compare fundamentals

Oncology Institute Account Relationship Matchups

Oncology Institute fundamental ratios Accounts

		2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding		64.4M	59.1M	66.2M	80.6M	73.7M	68.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncology Net Income From Continuing Ops vs Cost Of Revenue Analysis

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Cost Of Revenue

Oncology Institute fundamental ratios Correlations

Oncology Institute Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncology Institute fundamental ratios Accounts

Also Currently Popular

Additional Tools for Oncology Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 1.0	Non Current Liabilities Total
Net Working Capital	+ 1.0	Total Current Assets
Total Current Assets	+ 0.99	Other Current Liab
Other Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.99	Cash And Short Term Investments

Net Working Capital	- 0.94	Capital Stock
Capital Stock	- 0.92	Net Invested Capital
Property Plant And Equipment Gross	- 0.92	Retained Earnings
Capital Stock	- 0.91	Total Current Assets
Retained Earnings	- 0.91	Total Current Liabilities
Capital Stock	- 0.91	Total Assets